Affordable Access

deepdyve-link
Publisher Website

5-HT2 receptor activation alleviates airway inflammation and structural remodeling in a chronic mouse asthma model.

Authors
  • Flanagan, Thomas W1
  • Sebastian, Melaine N1
  • Battaglia, Diana M2
  • Foster, Timothy P2
  • Cormier, Stephania A3
  • Nichols, Charles D4
  • 1 Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA.
  • 2 Department of Microbiology, Immunology, And Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA.
  • 3 Department of Biological Sciences, Louisiana State University, 202 Life Sciences Building, Baton Rouge, LA, 70803, USA.
  • 4 Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA. Electronic address: [email protected]
Type
Published Article
Journal
Life sciences
Publication Date
Nov 01, 2019
Volume
236
Pages
116790–116790
Identifiers
DOI: 10.1016/j.lfs.2019.116790
PMID: 31626791
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Although the bulk of research into the biology of serotonin 5-HT2A receptors has focused on its role in the CNS, selective activation of these receptors in peripheral tissues can produce profound anti-inflammatory effects. We previously demonstrated that the small molecule 5-HT2 receptor agonist (R)-2,5-dimethoxy-4-iodoamphetamine [(R)-DOI] inhibits TNF-α-mediated proinflammatory signaling cascades and inflammation via 5-HT2A receptor activation and prevents the development of, and inflammation associated with, acute allergic asthma in a mouse ovalbumin (OVA) model. Here, we investigated the ability of (R)-DOI to reverse inflammation and symptoms associated with established asthma in a newly developed model of chronic asthma. An 18-week ovalbumin challenge period was performed to generate persistent, chronic asthma in BALB/c mice. Four once daily intranasal treatments of (R)-DOI were administered one week after allergen cessation, with respiratory parameters being measured by whole-body plethysmography (WBP). Cytokine and chemokine levels were measured by quantitative real-time polymerase chain reaction (qRT-PCR) in homogenized lung tissue, bronchoalveolar (BALF) fluid was analyzed for chemokine modulation by multiplex assays, and Periodic Acid-Schiff and Masson's Trichrome staining was performed to determine goblet cell infiltration and overall changes to lung morphology. 5-HT2 activation via (R)-DOI attenuates elevated airway hyperresponsiveness to methacholine, reduces pulmonary inflammation and mucus production, and reduces airway structural remodeling and collagen deposition by nearly 70%. Overall, these data provide support for the therapeutic potential of (R)-DOI and 5-HT2 receptor activation for the treatment of asthma, and identifies (R)-DOI as a novel therapeutic compound against pulmonary fibrosis. Copyright © 2019. Published by Elsevier Inc.

Report this publication

Statistics

Seen <100 times